Drug intelligence / Profile preview

TRTP-102

Development stage: Preclinical
Lead developer: CellinCells
Modality: Tissue Cells → Other Cell Types → Cell Therapies
Administration: Intraarticular

Overview

TRTP-102 is an injectable organoid-based regenerative therapy being developed by CellinCells for the treatment of osteoarthritis and meniscus damage. Utilizing the company's proprietary Tissue-Regenerative Therapeutic Platform (TRTP), the therapy involves the delivery of three-dimensional organoids directly into the joint. These organoids are designed to mimic the native tissue architecture and biological function of cartilage and meniscus, facilitating more effective tissue repair and regeneration compared to traditional single-cell therapies. TRTP-102 aims to address the underlying structural damage in joint diseases, potentially restoring mobility and reducing pain for patients.

Beyond the preview

Go deeper on TRTP-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRTP-102.

Explore the full profile